Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: A systematic review and meta-analysis

Clinical Microbiology and Infection

Volumn 21, Issue 7, 2015, Pages 665-673

  Steinmetz, T ^a   Eliakim Raz, N ^b,c   Goldberg, E ^b,c   Leibovici, L ^a,c   Yahav, D ^b,c  

^a Department of Medicine E ^*  (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Efficacy; Monitoring; MRSA; Serum concentration; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; HUMAN; KIDNEY INJURY; MEDICAL RECORD REVIEW; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGICAL EXAMINATION; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; TREATMENT FAILURE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; SERUM; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RENAL INSUFFICIENCY; SERUM; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84930824129     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.04.003     Document Type: Article

References (50)

1. Kollef M.H. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007, 45:S191-S195.
2. Sakoulas G., Moise-Broder P.A., Schentag J., et al. Relationship of MIC and bacterial activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
3. LaPlante K.L., Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004, 48:4665.
4. Stryjewski M.E., Szczech L.A., Benjamin D.K., Inriq J.K., Kanafani Z.A., Engemann J.J., et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007, 44:190.
5. Kim S.H., Kim K.H., Kim H.B., Kim N.J., Kim E.C., Oh M.D., et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008, 52:192.
6. Lamer C., de Beco V., Soler P., Calvat S., Faqon J.Y., Dombret M.C., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993, 37:281.
7. Albanèse J., Léone M., Bruguerolle B., Ayem M.L., Lacarell B., Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000, 44:1356.
8. Stein G.E., Wells E.M. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010, 26:571-588.
9. Moise P.A., Forrest A., Bhavnani S.M., Birmingham M.C., Schentag J.J. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000, 57:S4-S9.
10. Lodise T.P., Graves J., Evans A., Graffunder E., Helmecke M., Lomaestro B.M., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
11. Hidayat L.K., Hsu D.I., Quist R., Shrinier K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
12. Van Hal S.J., Paterson D.L., Lodise T.P. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013, 57:734-744.
13. Lodise T.P., Lomasetro B., Graves J., Drusano G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
14. Jeffers M.N., Isakow W., Doherty J.A., Micek S.T., Kollef M.H. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007, 20:1107-1115.
15. Zimmermann A.E., Katona B.G., Plaisance K.I. Association of vancomycin serum concentrations with outcomes in patients with Gram-positive bacteremia. Pharmacotherapy 1995, 15:85-91.
16. Pritchard L., Baker C., Leggett J., Sehdev P., Brown A., Bayley K.B. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010, 123:1143-1149.
17. Cohen E., Dadashev A., Drucker M., Samra Z., Rubinstein E., Garty M. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002, 49:155.
18. Black E., Lau T.T., Ensom M.H. Vancomycin-induced neutropenia: is it dose- or duration-related?. Ann Pharmacother 2011, 45:629-638.
19. Smith P.F., Taylor C.T. Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions. Pharmacotherapy 1999, 19:240.
20. Von Drygalski A., Curtis B.R., Bougie D.W., Mcfarland J.G., Ahl S., Limbu L., et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007, 356:904.
21. Reis A.G., Grisi S.J. Adverse effects of vancomycin in children: a review of 22 cases. Sao Paulo Med J 1997, 115:1452.
22. Clayman M.D., Capaldo R.A. Vancomycin allergy presenting as fever of unknown origin. Arch Intern Med 1989, 149:1425.
23. Rocha J.L., Kondo W., Baptista M.I., Da Cunha C.A., Martins L.T. Uncommon vancomycin-induced side effects. Braz J Infect Dis 2002, 6:196.
24. Polk R.E., Israel D., Wang J., Venitz J., Miller J., Stotka J. Vancomycin skin tests and prediction of "red man syndrome" in healthy volunteers. Antimicrob Agents Chemother 1993, 37:2139.
25. Vauthey L., Uçkay I., Abrassart S., Bernard L., Assal M., Ferry T., et al. Vancomycin-induced DRESS syndrome in a female patient. Pharmacology 2008, 82:138.
26. Boet S., Noblet C., Haas-Hubscher C., Picard D., Musette P., Dureuil B. Severe vancomycin-induced drug rash with eosinophilia and systemic symptoms syndrome imitating septic shock. Eur J Anaesthesiol 2009, 26:791.
27. Alexander, Greenberger P.A. Vancomycin-induced Stevens-Johnson syndrome. Allergy Asthma Proc 1996, 17:75.
28. Hicks R.W., Hernandez J. Perioperative pharmacology: a focus on vancomycin. AORN J 2011, 93:593.
29. Hepner D.L., Castells M.C. Anaphylaxis during the perioperative period. Anesth Analg 2003, 97:1381.
30. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
31. Review Manager (RevMan), version 5.2 2011, Nordic Cochrane Centre; Cochrane Collaboration, Copenhagen.
32. Chung J., Oh J.M., Cho E.M., Jang H.J., Hong S.B., Lim C.M. Optimal dose of vancomycin for treating methicillin resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth Intensive Care 2011, 39:1030-1037.
33. Holmes N.E., Turnidge J.D., Munckhof W.J., Robinson J.O., Korman T.M., O'Sullivan M.V., et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013, 57:1654-1663.
34. Wunderink R.G., Niederman M.S., Kollef M.H., Shorr A.F., Kunkel M.J., Baruch A., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012 Mar 1, 54:621-629.
35. Jeffers M.N., Isakow W., Doherty J.A., Mckinnon P.S., Ritchie D.J., Micek S.T., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health care-associated pneumonia specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130:947-955.
36. Hermsen E.D., Hanson M., Sankaranarayanan J., Stoner J.A., Florescu M.C., Rupp M.C. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010, 9:9-14.
37. Kullar R., Davis S.L., Taylor T.N., Kaye K.S., Rybak M.J. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 2012, 32:195-201.
38. Albur M.S., Bowker K., Weir I., MacGowan A. Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis 2012, 31:295-301.
39. Arshad S., Shoyinka A., Chen A., Jacobsen G., Zervos M. Evaluation of vacomycin serum trough concentrations and outcomes in meticillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2012, 40:474-475.
40. Chan J.D., Pham T.N., Wong J., Hessel M., Cuschieri J., Neff M., et al. Clinical outcomes of linezolid vs. vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis. J Intensive Care Med 2011, 26:385-391.
41. Forstner C., Dungl C., Tobudic S., Mitteregger D., Lagler H., Burgmann H. Predictors of clinical and microbiological treatment failure in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective cohort study in a region with low MRSA prevalence. Clin Microbiol Infect 2013, 19:E291-E297.
42. Mizokami F., Shibasaki M., Yoshizue Y., Noro T., Mizuno T., Furuta K. Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging 2013, 8:1015-1021.
43. Zelenitsky S., Rubinstein E., Ariano R., Lacovides H., Dodek P., Mirzanejad Y., et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 2013, 41:255-260.
44. Kullar R., Davis S.L., Levine D.P., Rybak M.J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011, 52:975-981.
45. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R.C., Craig W.A., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
46. Ye Z.K., Tang H.L., Zhai S.D. Benefits of therapeutic drug monitoring of vancomycin: systematic review and meta-analysis. PLoS One 2013, 8:e77169.
47. Chong Y.P., Park S.J., Kim H.S., Kim E.S., Kim M.N., Park K.H., et al. Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of osilates. Medicine (Baltimore) 2013, 92:98-108.
48. Ok H.S., Lee H.S., Park M.J., Kim K.H., Kim B.K., Wi Y.M., et al. Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study. Korean J Intern Med 2013, 28:678-686.
49. Kullar R., McKinnell J.A., Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for re-evaluating the 7-day expectation for MRSA bacteremia before switching therapy. Clin Infect Dis 2014, 59(10):1455-1461.
50. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.